TMEM14C is a Novel Biomarker for Prognosis And Diagnosis of Liver Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Transmembrane proteins (TMEMs) are frequently used as prognostic biomarkers for various cancer types, making them a significant area of interest in cancer research. The prognostic significance of transmembrane protein 14C (TMEM14C) and its association with tumor-infiltrating immune cells (TIICs) has not been explored in liver hepatocellular carcinoma (LIHC). This study aimed to assess the potential prognostic value of TMEM14C by conducting a comprehensive analysis of online databases on LIHC. We evaluated the potential of TMEM14C as a prognostic biomarker using online databases such as TIMER, GEPIA2, UALCAN, OSlihc, and LinkedOmics. We observed that the mRNA expression of TMEM14C was upregulated in LIHC than that in normal tissues. Upregulated TMEM14C expression was associated with worse prognosis based on the clinicopathological characteristics of patients with LIHC. Furthermore, TMEM14C expression was positively associated with TIICs. In the co-expression and functional enrichment analyses of TMEM14C, 7,401 genes were positively associated with TMEM14C, whereas 12,520 genes showed negative associations. The results of gene set enrichment analysis (GSEA)-Gene Ontology showed that TMEM14C-related co-expression genes were involved in protein localization to translational elongation, protein localization to the endoplasmic reticulum, and mitochondrial gene expression. Furthermore, GSEA-Kyoto Encyclopedia of Genes and Genomes analysis showed that these genes regulated ribosomes, oxidative phosphorylation, and spliceosomes. A survival map revealed that 28 and 24 genes that were positively associated with TMEM14C showed significant hazard ratios for overall survival and diseasefree survival, respectively. Our findings demonstrate that TMEM14C is a novel prognostic biomarker and a potential tumor immune therapeutic target in patients with LIHC.
Abstract
Transmembrane proteins (TMEMs) are frequently used as prognostic biomarkers for various cancer types, making them a significant area of interest in cancer research. The prognostic significance of transmembrane protein 14C (TMEM14C) and its association with tumor-infiltrating immune cells (TIICs) has not been explored in liver hepatocellular carcinoma (LIHC). This study aimed to assess the potential prognostic value of TMEM14C by conducting a comprehensive analysis of online databases on LIHC. We evaluated the potential of TMEM14C as a prognostic biomarker using online databases such as TIMER, GEPIA2, UALCAN, OSlihc, and LinkedOmics. We observed that the mRNA expression of TMEM14C was upregulated in LIHC than that in normal tissues. Upregulated TMEM14C expression was associated with worse prognosis based on the clinicopathological characteristics of patients with LIHC. Furthermore, TMEM14C expression was positively associated with TIICs. In the co-expression and functional enrichment analyses of TMEM14C, 7,401 genes were positively associated with TMEM14C, whereas 12,520 genes showed negative associations. The results of gene set enrichment analysis (GSEA)-Gene Ontology showed that TMEM14C-related co-expression genes were involved in protein localization to translational elongation, protein localization to the endoplasmic reticulum, and mitochondrial gene expression. Furthermore, GSEA-Kyoto Encyclopedia of Genes and Genomes analysis showed that these genes regulated ribosomes, oxidative phosphorylation, and spliceosomes. A survival map revealed that 28 and 24 genes that were positively associated with TMEM14C showed significant hazard ratios for overall survival and diseasefree survival, respectively. Our findings demonstrate that TMEM14C is a novel prognostic biomarker and a potential tumor immune therapeutic target in patients with LIHC.
참고문헌 (34)
- Kim HR, "The value of CDC42 effector protein 2 as a novel prognostic biomarker in liver hepatocellular carcinoma : a comprehensive data analysis", Osong Public Health Res Perspect, 14, pp.451~467 (2023)
- Paul C, "Hepatitis C virus core protein interacts with cellular metastasis suppressor Nm23-H1 and promotes cell migration and invasion", Arch Virol, 164, pp.1271~1285 (2019)
- Sangiovanni A, "Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance", Gastroenterology, 126, pp.1005~1014 (2004)
- Zheng X, "Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma", Front Immunol, 12, pp.729705~ (2021)
- Lee YT, "Risk stratification and early detection biomarkers for precision HCC screening", Hepatology, 78, pp.319~362 (2023)
- Gentles AJ, "The prognostic landscape of genes and infiltrating immune cells across human cancers", Nat Med, 21, pp.938~945 (2015)
- Bremnes RM, "The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer develop-ment, progression, and prognosis : emphasis on non-small cell lung cancer", J Thorac Oncol, 6, pp.824~833 (2011)
- Cabrita R, "Tertiary lymphoid structures improve immunotherapy and survival in melanoma", Nature, 577, pp.561~565 (2020)
- Angell HK, "PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer", Oncoimmunology, 8, pp.e1544442~ (2018)
- Hao X, "DNA methylation markers for diagnosis and prognosis of common cancers", Proc Natl Acad Sci U S A, 114, pp.7414~7419 (2017)
- Sia D, "Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features", Gastroenterology, 153, pp.812~826 (2017)
- Tian MX, "Tissue-infiltrating lymphocytes signature predicts survival in patients with early", intermediate stage hepatocellular carci-noma, 2019, pp.17, 106~
- Schmit K, "TMEM Proteins in Cancer : A Review", Front Pharmacol, 9, pp.1345~ (2018)
- An Y, "OSlihc : An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma", Front Pharmacol, 11, pp.875~ (2020)
- Vasaikar SV, "LinkedOmics : anal-yzing multi-omics data within and across 32 cancer types", Nucleic Acids Res, 46, pp.D956~D963 (2018)
- Ouyang X, "Identification of Diag-nostic Biomarkers and Subtypes of Liver Hepatocellular Carcinoma by Multi-Omics Data Analysis", Genes(Basel), 11, pp.1051~ (2020)
- Lee JG, "The actual five-year survival rate of hepatocellular carcinoma patients after curative resection", Yonsei Med J, 47, pp.105~112 (2006)
- Dapito DH, "Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4", Cancer Cell, 21, pp.504~516 (2012)
- Uehara T, "Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis", Toxicol Sci, 132, pp.53~63 (2013)
- Ostrand-Rosenberg S, "Immune surveillance : a balance between protumor and antitumor immunity", Curr Opin Genet Dev, 18, pp.11~18 (2008)
- Munhoz RR, "Recent advances in understanding antitumor immunity", F1000Res, 5, pp.2545~ (2016)
- Lazăr DC, "Prognostic significance of tumor immune micro-environment and immunotherapy : Novel insights and future perspectives in gastric cancer", World J Gastroenterol, 24, pp.3583~3616 (2018)
- Choi Y, "Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer", Gastric Cancer, 20, pp.602~611 (2017)
- Kurebayashi Y, "Landscape of immune microenvironment in hepa-tocellular carcinoma and its additional impact on histological and molecular classification", Hepatology, 68, pp.1025~1041 (2018)
- Sun H, "Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma", Hepatology, 70, pp.168~183 (2019)
- Hayez A, "High TMEM45A expression is correlated to epidermal keratinization", Exp Dermatol, 23, pp.339~344 (2014)
- Thomas-Gatewood C, "TMEM16A channels generate Ca2+-activated Cl-currents in cerebral artery smooth muscle cells", Am J Physiol Heart Circ Physiol, 301, pp.H1819~H1827 (2011)
- Foulquier F, "TMEM165 deficiency causes a congenital disorder of glycosylation", Am J Hum Genet, 91, pp.15~26 (2012)
- Malhotra K, "Identification of differentially expressed mRNAs in human fetal liver across gestation", Nucleic Acids Res, 27, pp.839~847 (1999)
- Cuajungco MP, "Abnormal accumulation of human transmembrane(TMEM)-176A and 176B proteins is associated with cancer pathology", Acta Histochem, 114, pp.705~712 (2012)
- Hrašovec S, "TMEM25 is a candidate biomarker methylated and down regulated in colorectal cancer", Dis Markers, 34, pp.93~104 (2013)
- Zhou X, "The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma", Cancer Genet Cytogenet, 177, pp.6~15 (2007)
- Qiao W, "Over-expression and biological function of TMEM48 in non-small cell lung carcinoma", Tumour Biol, 37, pp.2575~2586 (2016)
- Doolan P, "TMEM25, REPS2 and Meis 1 : favourable prognostic and predictive biomarkers for breast cancer", Tumour Biol, 30, pp.200~209 (2009)